.cls-1{fill:#f55014;}.cls-2{fill:#776e64;} Hem>Listing Nasdaq Stockholm Main Market Listing Nasdaq Stockholm Main Market Share this: IRLAB’s listing on the Nasdaq Stockholm Main Market Nasdaq Stockholm’s listing committee approved IRLAB’s application for admission to trading of the IRLAB’s shares of series A on the Nasdaq Stockholm Main Market on September 22, 2020. The approval is subject to fulfilment of customary conditions, including approval and registration of a prospectus by the Swedish Financial Supervisory Authority (granted on September 25, 2020). In short The first day of trading on Nasdaq Stockholm Main Market is expected to be Wednesday, September 30, 2020. The last day of trading on Nasdaq First North Premier Growth Market is expected to be Tuesday, September 29, 2020. The shares will continue to be traded under the same ticker (IRLAB A) and ISIN code (SE0012675361). No new shares will be issued in connection with the list change. The shareholders in IRLAB do not need to take any measures in connection with the list change. Press releases September 23, 2020: IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market Prospectus Download prospectus (Swedish only) Right click on the button to open in your browser as a new tab. IRLAB Therapeutics AB (publ) Arvid Wallgrens Backe 20 413 46 Göteborg +46 31 757 38 00 Copyright © 2021 IRLAB Integrity policy

.cls-1{fill:#f55014;}.cls-2{fill:#776e64;} Hem>Newsroom>Image library Image library Share this: CEO, Nicholas Waters Low resolution CFO, Viktor Siewertz Low resolution CMO, Joakim Tedroff Low resolution Chairman of the board, Gunnar Olsson Low resolution The ISP platform in use Low resolution Depicting work at IRLAB Low resolution IRLAB Therapeutics AB (publ) Arvid Wallgrens Backe 20 413 46 Göteborg +46 31 757 38 00 Copyright © 2021 IRLAB Integrity policy

.cls-1{fill:#f55014;}.cls-2{fill:#776e64;} Hem>Initial public offering 2017 Initial public offering 2017 Access to this information is limited to persons resident and physically present in Sweden and to authorized persons who are resident and physically present in other jurisdictions outside Canada, Japan, Australia, Japan, New Zealand, Singapore, South Africa, Switzerland, United States of America. Select the country in which you reside: Please Select Sweden Australia Canada Hongkong Japan New Zealand Singapore South Africa Switzerland United States of America Other Country Select the country in which you are currently physically present: Please Select Sweden Australia Canada Hongkong Japan New Zealand Singapore South Africa Switzerland United States of America Other Country Next IRLAB Therapeutics AB (publ) Arvid Wallgrens Backe 20 413 46 Göteborg +46 31 757 38 00 Copyright © 2021 IRLAB Integrity policy